Nature Reviews Cancer Impact Factor 2025

Nature Reviews Cancer is a premier review journal published by Springer Nature, delivering authoritative, high-impact coverage of oncology, cancer biology, tumor immunology, cancer genomics, metastasis, and therapeutic strategies. With an Impact Factor of 60.7 (Q1, Oncology), it ranks among the most influential publications in its field.

OVERVIEWAbout Nature Reviews Cancer

Nature Reviews Cancer was launched to provide the biomedical community with definitive, timely review articles that integrate mechanistic insights with clinical applications. The journal covers oncology, cancer biology, tumor immunology, cancer genomics, metastasis, and therapeutic strategies, making it essential reading for oncologists, cancer biologists, and pharmaceutical researchers.

Under Springer Nature’s editorial direction, the journal maintains stringent peer review standards and publishes only the most significant advances. Each article undergoes rigorous evaluation by field experts to ensure scientific accuracy, balance, and clinical relevance.

The journal particularly emphasizes articles bridging basic discovery and clinical practice, prioritizing contributions with clear translational implications for patient care or therapeutic development.

IMPACT METRICSNature Reviews Cancer Impact Factor 60.7

The journal’s latest Impact Factor is 60.7, placing it in Q1 within Oncology. This metric reflects the journal’s sustained influence in shaping research directions and clinical practice.

The Impact Factor is calculated as citations received in 2025 to articles published in 2023–2024, divided by citable items published in 2023–2024.

PUBLISHER INFOPublisher and Publication Details

Nature Reviews Cancer is published monthly by Springer Nature. The hybrid access model allows authors to choose traditional subscription publishing or make their articles immediately open access via the Springer Nature Open Choice program.

SCOPEJournal Scope and Subject Coverage

The journal publishes comprehensive reviews, perspectives, and opinion articles spanning oncology, cancer biology, tumor immunology, cancer genomics, metastasis, and therapeutic strategies. The editorial scope encompasses:

• Mechanistic reviews on disease pathogenesis and cellular processes
• Translational research bridging laboratory findings to clinical applications
• Therapeutic advances and emerging treatment strategies
• Technological innovations and methodological developments
• Clinical guidelines and evidence-based practice summaries
• Controversies and emerging topics in the field

SUBMISSION GUIDEAuthor Guidelines and Submission Process

Most articles in Nature Reviews Cancer are commissioned by the editorial team. However, unsolicited proposals are also considered. Prospective authors should submit a presubmission inquiry including a structured abstract, outline, and brief author biography.

Commissioned and accepted articles typically undergo:

1. Initial editorial review and scope assessment
2. Peer review by 2–3 independent experts in the field
3. Revision based on reviewer and editor feedback
4. Final acceptance and production editing

Manuscripts must be written in clear, concise English and follow the journal’s formatting guidelines. All submissions are handled through Springer Nature’s online editorial system.

EDITORIALEditorial Standards and Peer Review

The journal employs a comprehensive peer review process. Each manuscript is evaluated by field specialists for scientific accuracy, novelty, balance, and clinical relevance. Reviewers assess methodological soundness, data interpretation, and the significance of conclusions.

Editorial decisions are based on:

• Scientific rigor and methodological quality
• Novelty and significance of findings
• Clinical relevance and translational potential
• Balance and comprehensiveness of coverage
• Quality of presentation and clarity

INDEXINGAbstracting and Indexing Coverage

Nature Reviews Cancer is indexed in all major scientific databases, ensuring comprehensive discoverability of published research:

• Science Citation Index Expanded (SCIE)
• PubMed/MEDLINE
• Scopus
• Google Scholar
• Embase
• Current Contents/Clinical Medicine
• BIOSIS Previews

AUDIENCETarget Readership

The primary readership includes oncologists, cancer biologists, and pharmaceutical researchers. The journal also attracts pharmaceutical scientists, biotechnology professionals, and healthcare policy makers seeking authoritative summaries of current research and clinical developments.

ETHICSEthics and Open Science Practices

Authors must adhere to Springer Nature’s publication ethics policies. Requirements include disclosure of conflicts of interest, ethical approval for research involving human subjects or animals, and deposition of supporting data in appropriate repositories.

The journal supports open science through:

• Optional open access publication via Open Choice
• Mandatory data availability statements
• Support for preprint posting policies
• Transparent reporting guidelines

APC POLICYArticle Processing Charges

For authors choosing open access, the Article Processing Charge (APC) is approximately GBP 3,490 (approximately USD 4,400). Subscription articles incur no author fees. Fee waivers and discounts may be available for authors from low-income countries.

TIMELINEPublication Timeline and Review Duration

Initial editorial decisions are typically rendered within 2–4 weeks of submission. The peer review process generally takes 4–8 weeks. Production and online publication occur 4–6 weeks after acceptance.

RANKINGJournal Ranking and Competitiveness

With an Impact Factor of 60.7 and a Q1 ranking in Oncology, Nature Reviews Cancer is among the most competitive review journals in its discipline. Authors should ensure their manuscripts represent definitive, comprehensive coverage of high-priority topics.

METRICSAdditional Bibliometric Indicators

TRENDSCitation Trends and Impact Trajectory

Nature Reviews Cancer has maintained consistently high citation impact. Its review-focused publishing model ensures articles accumulate substantial citations over time. The journal’s emphasis on timely, clinically relevant topics positions it for continued influence.

SIMILAR JOURNALSRelated Journals and Alternatives

Researchers may also consider these related publications:

• Nature Reviews Gastroenterology & Hepatology
• Nature Reviews Endocrinology
• Nature Reviews Cancer
• Nature Reviews Neuroscience
• Nature Reviews Molecular Cell Biology
• Nature Reviews Drug Discovery

CITATION TOOLSHow to Cite This Journal

Standard citation format for Nature Reviews Cancer:

Nature Reviews Cancer. Springer Nature. ISSN: 1474-175X. Available at: https://www.nature.com/nri/ (accessed [date]).

FREQUENTLY ASKEDFAQ

What is the Impact Factor of Nature Reviews Cancer?

The Impact Factor is 60.7 (Q1, Oncology), reflecting its status as a leading review journal.

Who publishes Nature Reviews Cancer?

The journal is published by Springer Nature, a leading global research publisher headquartered in the United Kingdom.

Is Nature Reviews Cancer SCIE indexed?

Yes, the journal is indexed in Science Citation Index Expanded (SCIE), Scopus, PubMed/MEDLINE, and other major databases.

What is the ISSN of Nature Reviews Cancer?

The print ISSN is 1474-175X and the electronic ISSN (eISSN) is 1474-1768.

What is the APC for Nature Reviews Cancer?

The open access Article Processing Charge is approximately GBP 3,490 (approximately USD 4,400). No fees apply for subscription publishing.

What is the acceptance rate of Nature Reviews Cancer?

As a review journal, most articles are commissioned by the editors. The acceptance rate for unsolicited proposals is competitive, typically below 15%.